Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Natural Products >  Lignans >  ASARININ

ASARININ

Basic information Safety Supplier Related

ASARININ Basic information

Product Name:
ASARININ
Synonyms:
  • (-)-SESAMINE
  • (-)-ASARININ
  • ASARININ
  • EPI-SESAMIN
  • (-)-5,5'-[(1R,3aα,4S,6aα)-Tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl]bis[1,3-benzodioxole]
  • 5,5'-[(1R,3aα,4S,6aα)-Tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl]bis(1,3-benzodioxole)
  • L-Asarinin
  • 5-[4-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-1-yl]-1,3-benzodioxole
CAS:
133-04-0
MF:
C20H18O6
MW:
354.35
Product Categories:
  • Lichen Products
Mol File:
133-04-0.mol
More
Less

ASARININ Chemical Properties

Melting point:
121°
alpha 
D20 -118.6°; D23 -122° (chloroform)
Boiling point:
504.4±50.0 °C(Predicted)
Density 
1.385±0.06 g/cm3(Predicted)
storage temp. 
-20°C Freezer
solubility 
Chloroform (Slightly), DMSO (Slightly, Sonicated)
form 
Solid
color 
White to Off-White
More
Less

ASARININ Usage And Synthesis

Description

Asarinin is a lignan that has been found in A. sieboldii. It is an epimer of sesamin and a noncompetitive inhibitor of Δ5-desaturase (Ki = 0.28 mM). It is selective for Δ5-desaturase over Δ6- and Δ9-desaturase. Asarinin is cytotoxic to A2780 and SKOV3 ovarian cancer cells (IC50s = 38.45 and 60.87 μM, respectively) but not immortalized ovarian surface epithelial cells (IC50 = >200 μM). It induces apoptosis and activates caspase-3, -8, and -9 in A2780 and SKOV3 cells.

Chemical Properties

White needle-like crystals, soluble in boiling methanol, ethanol, chloroform, acetone, benzene, practically insoluble in water, from A. sarum .sieboldii pepper pepper Zanthoxylum piperitum, hairy puffball Paulownia tomentosa, two-faced needle.

Uses

l-Asarinin in combination with pellitorine is a potential larvicides for the control of insecticide-resistant mosquito populations. Possesses antimicrobial activity.

in vivo

(-)-Asarinin (5-20 mg/kg; gavage; once daily; 16 weeks) improves the morphology of gastric mucosal glands, alleviate intestinal metaplasia, inhibit the STAT3 pathway, promote ROS accumulation, and induce apoptosis of gastric mucosal cells in the N-Nitroso-N-methylurea (MNU) (HY-34758)-induced mouse model of gastric precancerous lesions[1].
(-)-Asarinin (5.0 mg/kg; oral administration; before intranasal OVA challenge) significantly inhibits the allergic reaction, reduces paw swelling and Evans blue exudation in mice, and decreases the degree of mast cell degranulation in the skin in the OVA-induced passive cutaneous anaphylaxis mouse model[3].
(-)-Asarinin (2.50 mg/kg; oral administration) reduces the concentrations of histamine, TNF-α, MCP-1, IL-4, and IL-5 in the serum of mice in the OVA - induced systemic anaphylaxis mouse model<[3].
(-)-Asarinin (5.0 mg/kg; oral administration; once daily; from day 21-28) significantly inhibits the scratching and sneezing responses of mice, reduces the concentrations of histamine, total IgE, and IL-4 in the serum of mice, and alleviates the inflammatory infiltration and thickening of the nasal mucosa in the OVA-induced allergic rhinitis mouse model[3].
(-)-Asarinin (2.5 mg/kg, 5.0 mg/kg, 10 mg/kg; oral administration) inhibits paw swelling and Evans blue exudation in mice and reduces the concentrations of histamine, TNF-α, MCP-1, and IL-8 in the serum in the C48/80-induced allergic reaction mouse model[3].
C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model3 5.0 mg/kg Oral administration Significantly suppressed passive cutaneous anaphylaxis (PCA) in mice, reduced the degree of swelling and Evens blue exudation of mice paw, and decreased the degree of degranulation of MCs in skin. C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model3 2.50 mg/kg Oral administration Significantly reduced the concentration of histamine, TNF-α, MCP-1, IL-4 and IL-5 in mice serum. C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model3 5.0 mg/kg Oral administration, once daily, from day 21 - 28 Significantly inhibited the scratching and sneezing response of mice, reduced the concentration of histamine, total IgE, and IL - 4 in mice serum, and attenuated the inflammatory infiltrates and nasal mucosa incrassation in the AR mice. C57BL/6 mice (male, 18-22 g), C48/80-induced allergic reaction model3 2.5 mg/kg, 5.0 mg/kg, 10 mg/kg Oral administration Reduced C48/80-induced paw swelling and Evens blue exudation, and decreased the concentration of histamine, TNF-α, MCP-1 and IL-8 in mice serum.

Animal Model:Animal Model: SPF-grade BALB/c mice (male and female, 18-20 g, 4-week-old), established by administration of carcinogenic agent MNU[1]
Dosage:20 mg/kg, 5 mg/kg
Administration:Gavage, once daily, 16 weeks
Result:Reversed the deterioration of the gastric mucosal glands' morphology, reduced the severity of intestinal metaplasia, promoted ROS accumulation, inhibited the STAT3 pathway, and induced apoptosis in the gastric mucosa of GPL mice.
Animal Model:C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model[3]
Dosage:5.0 mg/kg
Administration:Oral administration
Result:Significantly suppressed passive cutaneous anaphylaxis (PCA) in mice, reduced the degree of swelling and Evens blue exudation of mice paw, and decreased the degree of degranulation of MCs in skin.
Animal Model:C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model[3]
Dosage:5 mg/kg
Administration:Oral administration, once daily, from day 21-28
Result:Significantly inhibited the scratching and sneezing response of mice, reduced the concentration of histamine, total IgE, and IL - 4 in mice serum, and attenuated the inflammatory infiltrates and nasal mucosa incrassation in the AR mice.
Animal Model:C57BL/6 mice (male, 18-22 g), OVA-induced passive cutaneous anaphylaxis model3
Dosage:2.50 mg/kg
Administration:Oral administration
Result:Significantly reduced the concentration of histamine, TNF-α, MCP-1, IL-4 and IL-5 in mice serum.
Animal Model:C57BL/6 mice (male, 18-22 g), C48/80-induced allergic reaction model3
Dosage:2.5 mg/kg, 5.0 mg/kg, 10 mg/kg
Administration:Oral administration
Result:Reduced C48/80-induced paw swelling and Evens blue exudation, and decreased the concentration of histamine, TNF-α, MCP-1 and IL-8 in mice serum.

target

IL Receptor | IFN-γ | CXCR | TLR

References

[1] MIRAN JEONG. (-)-Asarinin from the Roots of Asarum sieboldii Induces Apoptotic Cell Death via Caspase Activation in Human Ovarian Cancer Cells.[J]. Molecules, 2018, 23 8. DOI: 10.3390/molecules23081849
[2] SAKAYU SHIMIZU. Inhibition of Δ5-desaturase in polyunsaturated fatty acid biosynthesis by (?)-asarinin and (?)-epiasarinin[J]. Phytochemistry, 1992, 31 3: Pages 757-760. DOI: 10.1016/0031-9422(92)80008-3

ASARININSupplier

Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Sichuan Kulinan Technology Co., Ltd
Tel
400-1166-196 18981987031
Email
cdhxsj@163.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
BioBioPha Co., Ltd.
Tel
0871-65217109 13211707573;
Email
y.liu@mail.biobiopha.com
ShangHai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847 13636370518
Email
shyysw007@163.com
More
Less

ASARININ(133-04-0)Related Product Information